Shots:
- Nanjing Leads Biolabs has enrolled the first patient in P-Ib/II trial assessing opatisumab as monotx. & in combination with toripalimab, for the treatment of 1L advanced melanoma in China
- Additionally, Opatisumab is being evaluated as monotx. in a registrational study for EP-NEC that completed enrolment in Aug 2025, & is also under investigation in multiple P-II trials with CT for 1L SCLC & 1/2L NSCLC
- Opatisumab, a PD-L1/4-1BB dual antibody designed to block PD-1/L1 immunosuppression & boost 4-1BB–driven T-cell activation to convert “cold” tumors into “hot,” has shown superior efficacy as a monotx. & with CT in ongoing trials for immune-cold EP-NEC
Ref: Nanjing Leads Biolabs | Image: Nanjing Leads Biolabs | Press Release
Related News:- Merck Reports P-III (STRIDE-13) Trial of Capvaxive for Active Immunization Against Pneumococcal Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
